Alexey Manikhas

TL;DR: The addition of neoadjuvant and adjuvant trastuzumab to neoadvuvant chemotherapy should be considered for women with HER2-positive locally advanced or inflammatory breast cancer to improve event-free survival, survival, and clinical and pathological tumour responses.

TL;DR: In this paper, the authors evaluated the effect of adding lapatinib, a dual tyrosine kinase inhibitor blocking epidermal growth factor receptor and HER2, to the aromatase inhibitor letrozole as first-line treatment of hormone receptor-positive metastatic breast cancer.

TL;DR: It is demonstrated that a combined targeted strategy with letrozole and lapatinib significantly enhances PFS and clinical benefit rates in patients with MBC that coexpresses HR and HER2.

TL;DR: Everolimus significantly increased letrozole efficacy in neoadjuvant therapy of patients with ER-positive breast cancer and the safety profile was consistent with historical results of everolimus monotherapy.

TL;DR: Fulvestrant has superior efficacy and is a preferred treatment option for patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not received previous endocrine therapy compared with a third-generation aromatase inhibitor, a standard of care for first-line treatment of these patients.